Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about Progression: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| Progressive Multiple Sclerosis | involved_in | disease | 0.90 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
| Hypothesis | Score | Disease | Analysis |
|---|---|---|---|
| Elevated CSF/Serum Albumin Quotient Predicts Neurodegenerati | 0.850 | - | What blood-brain barrier permeability ch |
| Lysosomal Acidification Failure: Convergent GBA1/LAMP2A–medi | 0.700 | neurodegeneration | - |
| Tau/MAP6 antagonism in neurodegeneration progression | 0.650 | neurodegeneration | View |
| Heterogeneous astrocyte activation states differentially imp | 0.640 | Alzheimer's disease | SEA-AD Single-Cell Analysis: Cell-Type V |
| Reactive astrocytes and cholinesterase-rich low-acetylcholin | 0.440 | neurodegeneration | What determines the temporal sequence of |
| DNA Hypomethylation at P2RY12 Promoter Correlates with Disea | 0.440 | neurodegeneration | What determines P2RY12 receptor expressi |
| Epigenetic Silencing of Tumor Suppressor Genes in Cancer Pro | 0.438 | - | - |
| MT1 Receptor Activation at Low Doses Synchronizes Suprachias | 0.405 | - | What is the minimum effective dose of tr |
| Epigenetic Age Acceleration Moderates the Amyloid-to-Tau Con | 0.343 | - | Epigenetic clocks as biomarkers for Alzh |
Scientific analyses that reference this entity
No analyses mention this entity
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| iPSC-NPC effects on astrocytes in vitro ICH model | exploratory | intracerebral hemorrhage | 0.900 | 0.00 | in vitro ICH cell culture mode | completed | N/A |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Brain atrophy patterns in anti-IgLON5 disease. [PMID:40650880] | Yogeshwar SM, Bartels F, Grüter T, Muñiz | Brain | 2026 | 0 |
| Potential diagnostic markers in Alzheimer's disease: current perspectives and fu [PMID:40911035] | Zheng M, Wang S, Jia J | Neurodegener Dis Manag | 2026 | 0 |
| Kidney Function, Alzheimer Disease Blood Biomarkers, and Dementia Risk in Commun [PMID:41337685] | Gasparini F, Valletta M, Vetrano DL, Ber | Neurology | 2026 | 0 |
| The role of astrocytes in Alzheimer's disease: Pathophysiology, biomarkers, and [PMID:41527736] | Abedin MJ, Kastanenka KV | J Alzheimers Dis | 2026 | 0 |
| Biomarker-integrated prognostic stagings for Alzheimer's Disease. [PMID:41622252] | Shin D, Lee S, Kim JP, Jang H, Yun J et | Nat Commun | 2026 | 0 |
| Prognostic Value of Plasma NfL and GFAP for Conversion to Alzheimer's Disease an [PMID:41703957] | Özkurt Ç, Kelicen-Uğur P | Biomarkers | 2026 | 0 |
| From scaffold to effector: reframing GFAP in neurodegeneration. [PMID:41775321] | Lu YH, Zhu XP, Li S, Zhang FN, Cai CB et | J Adv Res | 2026 | 0 |
| Translating neurofilament light chain testing into clinical practice: a multidis [PMID:41831326] | Furlan R, Di Sapio A, Ferraro D, Rossi E | Clin Chem Lab Med | 2026 | 0 |
| Role of astrocyte biomarker GFAP in early diagnosis and prognosis assessment of [PMID:41850459] | Li S, Wei S, Wang L, Yu T, Wang H et al. | Int J Biol Macromol | 2026 | 0 |
| Impaired glymphatic function is associated with synaptic loss in cognitive impai [PMID:41454064] | He K, Wang J, Wu J, Chen X, Chen H, Li J | European journal of nuclear me | 2026 | 0 |
| Cerebral FURIN deficiency impairs astrocytic lipophagy through ITGAV maturation. [PMID:41376284] | Xie XY, Wang L, Xie SQ, Zhou GF, Wen QX, | Autophagy | 2026 | 0 |
| Alzheimer's Disease as a Disorder of Neuroimmune Dysregulation. [PMID:41745721] | Aranda-Abreu GE, Rojas-Durán F, Hernánde | Neurology international | 2026 | 0 |
| Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. [PMID:40044789] | ["Qi Chao", "L\u00f6vestam Sofia", "Murz | Nature structural & molecular | 2025 | 0 |
| Childhood Asthma and Allergy Are Related to Accelerated Epigenetic Aging. [PMID:40346984] | Leskien M, Thiering E, Yu Z | Allergy | 2025 | 0 |
| Epigenetic age acceleration and allergic diseases: a bidirectional two-sample Me [PMID:40618086] | Sun J, Fan G, Hu L | Clin Epigenetics | 2025 | 0 |
| Tau filaments with the Alzheimer fold in human MAPT mutants V337M and R406W. [PMID:40044789] | ["Qi Chao", "L\u00f6vestam Sofia", "Murz | Nature structural & molecular | 2025 | 0 |
| DNA methyltransferase 1 (DNMT1) promotes cyst growth and epigenetic age accelera [PMID:38782200] | Zhou JX, Li LX, Zhang H | Kidney Int | 2024 | 0 |
| Endolysosomal impairment by binding of amyloid beta or MAPT/Tau to V-ATPase and [PMID:36843263] | Kim SH, Cho YS, Kim Y, Park J, Yoo SM, G | Autophagy | 2023 | 0 |
| Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a ph [PMID:37095250] | Mummery CJ, Börjesson-Hanson A, Blackbur | Nature medicine | 2023 | 0 |
| Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer's disease: a ph [PMID:37095250] | Mummery CJ, Börjesson-Hanson A, Blackbur | Nature medicine | 2023 | 0 |
Multi-agent debates referencing this entity
No debates reference this entity
Hypotheses and analyses mentioning Progression in their description or question text
Score: 0.440 · neurodegeneration · 2026-04-21
## Mechanistic Overview DNA Hypomethylation at P2RY12 Promoter Correlates with Disease Progression starts from the claim
Score: 0.405 · unknown disease · 2026-04-26
At doses of 25-50 mg, trazodone's metabolite mCPP exhibits partial agonist activity at melatonin MT1 receptors, phase-ad
Score: 0.343 · unknown disease · 2026-04-25
Concise Statement: There exists a critical threshold of epigenetic age acceleration (~4–6 years above chronological age